Best PDUFA Dates Q2 2026: FDA Approval Catalysts Every Biotech Trader Must Watch

PDUFA (Prescription Drug User Fee Act) dates are the single most important catalysts in biotech trading. These are the deadlines by which the FDA must make approval decisions on new drugs — and they create massive, predictable volatility events that traders can position around.

Q2 2026 (April–June) is packed with high-impact PDUFA dates across multiple therapeutic areas. Here are the dates you need on your calendar.

Why PDUFA Dates Matter for Traders

Biotech stocks typically follow a predictable pattern around PDUFA dates:

• 2-4 weeks before: The “PDUFA run-up” — stocks often gain 15-40% as traders position for approval
• Day of decision: Binary event — stocks can gap 50-300% up on approval or drop 40-80% on rejection
• Post-decision: Approved drugs often see continued momentum; rejections can take months to recover

Q2 2026 PDUFA Calendar

April 2026

BIIB (Biogen) — April 3, 2026 | NDA

Biogen has an NDA decision expected. As one of the largest biotech companies, BIIB PDUFA dates attract significant institutional attention. Watch for options activity and volume spikes 2-3 weeks prior.

DNLI (Denali Therapeutics) — April 5, 2026 | BLA | Hunter Syndrome

Denali BLA for Hunter syndrome represents a potential breakthrough in rare disease treatment. Rare disease approvals tend to have higher approval rates (70-80%) and can command premium pricing, making this a high-conviction setup for traders.

REPL (Replimune) — April 10, 2026 | BLA | Advanced Melanoma

Replimune oncolytic immunotherapy for advanced melanoma. The oncology space is competitive, but novel mechanisms can still drive significant approvals. This is a small-cap with high squeeze potential if approved.

TVTX (Travere Therapeutics) — April 13, 2026 | NDA

Travere has been a consistent performer in the kidney disease space. An NDA approval could significantly expand their commercial portfolio and drive institutional buying.

GRCE (Grace Therapeutics) — April 23, 2026 | NDA | Subarachnoid Hemorrhage

Grace Therapeutics targets aneurysmal subarachnoid hemorrhage (aSAH) — a critical, underserved neurological condition. First-in-class potential means minimal competition risk if approved.

AXSM (Axsome Therapeutics) — April 30, 2026 | sNDA | Alzheimer Disease

Axsome supplemental NDA in Alzheimer disease. The Alzheimer market is enormous ($10B+ opportunity), and any new approved treatment drives massive investor interest. This is a label expansion that could significantly increase revenue potential.

May 2026

BIIB (Biogen) — May 24, 2026 | NDA

Biogen second PDUFA date of the quarter. Two FDA decisions in one quarter is rare for a large-cap biotech and creates double catalyst opportunity for traders.

MNKD (MannKind) — May 29, 2026 | NDA

MannKind has a loyal retail following and high short interest, making it a prime squeeze candidate on approval. The combination of PDUFA catalyst + high SI creates the perfect setup for explosive moves.

June 2026

ARVN (Arvinas) — June 5, 2026 | NDA | Breast Cancer

Arvinas protein degrader technology represents a novel approach to estrogen receptor-positive breast cancer. As a first-in-class PROTAC therapy, approval would validate an entirely new drug modality and could drive significant M&A interest from large pharma.

ACHV (Achieve Life Sciences) — June 20, 2026 | NDA | Nicotine Dependence

Achieve targets the massive smoking cessation market. With millions of potential patients and limited current options, a new FDA-approved treatment could capture significant market share quickly.

How to Trade PDUFA Dates

The Run-Up Strategy

Most biotech traders do not hold through the binary event. Instead, they:

1. Enter 3-4 weeks before PDUFA — during the accumulation phase
2. Monitor volume and options flow — unusual activity signals informed money positioning
3. Exit 1-3 days before the decision — capturing the run-up while avoiding the binary risk

Key Signals to Watch

• Short interest changes: Shorts covering before PDUFA = bullish signal
• Insider buying: Insiders purchasing shares before their own PDUFA = highest conviction signal
• Cash runway: Companies with strong cash do not need the approval to survive — lower risk
• Options IV: Implied volatility expansion tells you how big the market expects the move to be

Track All PDUFA Dates with BioRadar

BioRadar tracks every upcoming PDUFA date alongside real-time short interest, insider trades, cash runway analysis, and AI-powered trade signals. Our PDUFA Calendar shows all upcoming FDA decision dates with countdown timers, and our Dashboard gives you the complete picture for any biotech ticker.

Create a free account to start tracking PDUFA dates and get alerts before key catalysts.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. PDUFA dates are binary events with significant risk. Always do your own research and consider your risk tolerance before trading biotech stocks.